SARS-CoV-2 B.1.1.529 (Omicron) Variant — United States, December 1–8, 2021

@article{Team2021SARSCoV2B,
  title={SARS-CoV-2 B.1.1.529 (Omicron) Variant — United States, December 1–8, 2021},
  author={Cdc Covid- Response Team},
  journal={Morbidity and Mortality Weekly Report},
  year={2021},
  volume={70},
  pages={1731 - 1734}
}
A new variant of SARS-CoV-2 (the virus that causes COVID-19), B.1.1.529 (Omicron) (1), was first reported to the World Health Organization (WHO) by South Africa on November 24, 2021. Omicron has numerous mutations with potential to increase transmissibility, confer resistance to therapeutics, or partially escape infection- or vaccine-induced immunity (2). On November 26, WHO designated B.1.1.529 as a variant of concern (3), as did the U.S. SARS-CoV-2 Interagency Group (SIG)* on November 30. On… 
View PDF
66 Citations
Background Citations
2

66 Citations

Citation Type

Citation Type

Investigation of a SARS-CoV-2 B.1.1.529 (Omicron) Variant Cluster — Nebraska, November–December 2021
TLDR
Phylogenetic analysis was conducted to determine if this cluster of six probable cases of COVID-19 represented an independent introduction of Omicron into the United States, and a detailed epidemiologic investigation was conducted.
SARS-CoV-2 B.1.1.529 (Omicron) Variant Transmission Within Households — Four U.S. Jurisdictions, November 2021–February 2022
TLDR
Multicomponent COVID-19 prevention strategies, including up-to-date vaccination, isolation of infected persons, and mask use at home, are critical to reducing Omicron transmission in household settings.
Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants — United States, June 2021–January 2022
TLDR
The dynamic landscape of Sars-CoV-2 variants in 2021, including Delta- and Omicron-driven resurgences of SARS-Cov-2 transmission across the United States, underscores the importance of robust genomic surveillance efforts to inform public health planning and practice.
Emerging evidence on Omicron (B.1.1.529) SARS‐CoV‐2 variant
COVID's Omicron variant has sparked a slew of concerns across the globe. This review aims to provide a brief overview of what we know about the Omicron variant right now. The new variant has been…
Omicron: a chimera of two early SARS-CoV-2 lineages
TLDR
At least one recombination event occurred in the origin and evolutionary history of the prototype Omicron variant of SARS-CoV-2, which is proposed to be derived from the recombination of two early PANGO lineages of Sars-Cov-2.
Is Omicron the end of pandemic or start of a new innings?
COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence - 25 U.S. Jurisdictions, April 4-December 25, 2021.
TLDR
The highest impact of booster doses against infection and death compared with full vaccination without booster doses was recorded among persons aged 50-64 and ≥65 years, and eligibility to stay up to date with COVID-19 vaccinations.
Importation and Transmission of SARS-CoV-2 B.1.1.529 (Omicron) Variant of Concern in Korea, November 2021
TLDR
In November 2021, 14 international travel-related severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.529 (omicron) variant of concern (VOC) patients were detected in South Korea and community transmission of the omicron VOC was revealed.
Shedding of SARS-CoV-2 for 85 Days in COVID-19 Patients With Type 2 Diabetes Mellitus and Lung Metastasis: A Case Report
TLDR
The patient was finally discharged from the hospital under the treatment of antiviral, hypoglycaemic, anti-anxiety, and a combination of Chinese and Western medicine, and the patient's epidemiological history, diagnosis, testing, and treatment process were introduced.
Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
TLDR
These findings suggest that among individuals seeking testing for COVID-like illness in the US in December 2021, receipt of 3 doses of mRNA CO VID-19 vaccine (compared with unvaccinated and with receipt of 2 doses) was less likely among cases with symptomatic SARS-CoV-2 infection.
...
1
2
3
4
5
...

References

SHOWING 1-2 OF 2 REFERENCES
Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool
TLDR
Phylogenetic Assignment of Named Global Outbreak Lineages (pangolin), a computational tool that has been developed to assign the most likely lineage to a given SARS-CoV-2 genome sequence according to the Pango dynamic lineage nomenclature scheme is presented.
Reducing travel-related SARS-CoV-2 transmission with layered mitigation measures: symptom monitoring, quarantine, and testing
TLDR
Quarantine is an effective measure to reduce SARS-CoV-2 transmission risk from travelers and can be enhanced by the addition of symptom monitoring and testing, which can complement recommendations such as social distancing, using masks, and hand hygiene to further reduce risk during and after travel.